default author photo

Delphine Legoupil

CHU de Brest

SCHOLARLY PAPERS

2

DOWNLOADS

92

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA

Number of pages: 44 Posted: 13 Oct 2025
Gustave Roussy, University of Bordeaux - CHU de Bordeaux, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Nantes - CHU Nantes, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Eugene Marquis, CHU de Brest, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Besançon - Université de Franche-Comté, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Université Paris Cité, affiliation not provided to SSRN, CHU Nimes, University of Angers - CHU Angers, affiliation not provided to SSRN, CHU Dijon Bourgogne, affiliation not provided to SSRN, CHU Nancy, affiliation not provided to SSRN, affiliation not provided to SSRN, Hôpital Saint-Louis and Université de Lille - CHU de Lille
Downloads 49 (1,074,648)

Abstract:

Loading...

Cemiplimab, cutaneous squamous cell carcinoma, anti-PD1, comparative study

2.

Survival outcomes of adjuvant therapy in resected stage III melanoma: results from a real-life cohort study (TAMARIS)

Number of pages: 28 Posted: 20 Oct 2025
affiliation not provided to SSRN, University of Nantes - CHU Nantes, University of Claude Bernard Lyon 1 - Centre Léon Bérard, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, CHU de Brest, Universite Paris Descartes - Assistance Publique - Hôpitaux de Paris, University of Nantes, CHU de Montpellier, University of Nantes, affiliation not provided to SSRN and University of Besançon - Université de Franche-Comté
Downloads 43 (1,222,651)

Abstract:

Loading...

Melanoma, adjuvant treatment, Immunotherapy, BRAFi/MEKi, anti-PD-1, BRAF V600, overall survival, Recurrence-free survival